Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Xiaomi Shares Jump on Europe EV Expansion Plan 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
OpenAI Nears Astra AI Model Launch With Safety Focus 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
REDWOOD CITY, Calif., March 01, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at two upcoming investor healthcare conferences.
- Management participation in a fireside chat at the 38th Cowen & Company Healthcare Conference on Monday, March 12th at 2:50 p.m. ET taking place in Boston, MA.
- Management participation in a fireside chat is scheduled at Barclays Global Healthcare Conference on Wednesday, March 14th at 11:15 a.m. ET taking place in Miami, FL.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
